PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.00 - 0.01
0.00 - 0.02
1.30M / 496.9K (Avg.)
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.00%
Negative EBIT growth while XRF.AX is at 0.00%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-0.00%
Negative operating income growth while XRF.AX is at 0.00%. Joel Greenblatt would press for urgent turnaround measures.
-0.00%
Negative net income growth while XRF.AX stands at 0.00%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-33.33%
Negative EPS growth while XRF.AX is at 0.00%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-33.33%
Negative diluted EPS growth while XRF.AX is at 0.00%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.40%
Share change of 0.40% while XRF.AX is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.00%
FCF growth of 0.00% while XRF.AX is zero. Bruce Berkowitz would see if modest improvements in free cash can accelerate further.
-68.05%
Negative 10Y revenue/share CAGR while XRF.AX stands at 93.04%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-25.04%
Negative 5Y CAGR while XRF.AX stands at 50.18%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
8.04%
3Y revenue/share CAGR under 50% of XRF.AX's 71.31%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
122.08%
Positive long-term OCF/share growth while XRF.AX is negative. John Neff would see a structural advantage in sustained cash generation.
232.93%
Positive OCF/share growth while XRF.AX is negative. John Neff might see a comparative advantage in operational cash viability.
298.27%
Positive 3Y OCF/share CAGR while XRF.AX is negative. John Neff might see a big short-term edge in operational efficiency.
125.52%
Below 50% of XRF.AX's 847.82%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
624.30%
5Y net income/share CAGR above 1.5x XRF.AX's 7.62%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
183.28%
Positive short-term CAGR while XRF.AX is negative. John Neff would see a clear advantage in near-term profit trajectory.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
4375.96%
3Y equity/share CAGR above 1.5x XRF.AX's 10.52%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.40%
We have a declining book value while XRF.AX shows 0.00%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
1.55%
R&D growth of 1.55% while XRF.AX is zero. Bruce Berkowitz checks if the moderate investment leads to meaningful product differentiation.
No Data
No Data available this quarter, please select a different quarter.